PhoreMost and The Wistar Institute join forces to find new druggable targets

10 March 2016

UK-based biotech company PhoreMost announced on Thursday that it had entered into a collaboration with US biomedical center The Wistar Institute to identify new druggable targets in cancer, aging and the immune system.

Most disease driving targets are seen as undruggable because they can appear structurally resistant to chemical intervention, especially when viewed outside of a cell in a static crystallized form.

PhoreMost has developed Siteseeker, a novel phenotypic screening platform that uses the dynamics of a live-cell environment to uncover hidden druggable target sites across the entire human genome, then quickly converts this information into novel small-molecule therapeutics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK